ABSCINT’s Post

Juggling 15+ systems for ONE clinical trial is crazy! Our webcast (ft. GSK, Medable, & Alcanza Research) dives into how a unified platform can streamline e-stuff (Consent, COA, etc.) & sensor data for a smooth, end-to-end ride. Level up your research game! Watch Video: https://lnkd.in/gMPBeSk6 #pharmaindustry #digitaltransformation #clinicaltrials #digitaltrials #pharmaceuticaltechnology

Topics in this presentation include: How specialized manufacturing expertise can streamline the transition from feasibility testing to commercial production, enhancing patient health outcomes. How outsourcing can lead to significant reductions in capital investment and expedite the time to market for microfluidic devices and other life science consumables. The true costs of product development and manufacturing, including hidden expenses related to facilities, equipment and administrative overhead. #microfluidic #ivd #diagnostics #laboratorytechnology #commercialmanufacturing #invitrodiagnostics #microfludiics #microfluidicsbassedsystem #cdmo #cmo #commercialization #heor #marketaccess #complimentarywebinar #freerecopy https://lnkd.in/gM-5er37

Can biomedical innovators actually be patient-centric? Does it require an altogether more pateint-centric ecosystem? Clinical trials, regulatory, care settings...supply chains? Michael Chiu outlines the approach to a more patient-centric manufacturing ecosystem as envisioned by Erbi Biosystems, a part of MilliporeSigma.

Can biomedical innovators actually be patient-centric? Does it require an altogether more pateint-centric ecosystem? Clinical trials, regulatory, care settings...supply chains? Michael Chiu outlines the approach to a more patient-centric manufacturing ecosystem as envisioned by Erbi Biosystems, a part of MilliporeSigma.

With a focus on the individual you can concentrate care options for the best results. See how Michael and his company's approach to patient-centric care has changed the landscape of the biomedical manufacturing world.

Enhancing CAR-T therapy development: harnessing cell selection flexibility Advancements in #CARTcelltherapy have driven the need for innovative, closed, automated, and space-efficient manufacturing platforms. Considering each therapeutic product requires a unique manufacturing process, flexibility in process design and automation is essential to accommodate these varying needs. Next month, Lonza’s Tamara Laskowski (Senior Director, Clinical Development) and Nuala Trainor (Director, R&D, Personalized Medicine) will introduce a novel automated manufacturing platform that can be adapted to different #CARTmanufacturing processes by positively or negatively selecting #Tcells directly from apheresis, and discuss the advantages associated with this approach. Register for this #webinar below:

Discover how our custom solutions empower researchers to achieve more! Read our case study with LumiraDx to see how the creation of specialised reagents propelled their diagnostic technologies forward. This case study exemplifies our commitment to delivering precision and innovation in product development: https://bit.ly/4bpflBO #reagents #mRNA

Check out Key Tech Inc.‘s approach for evaluating assays for automation! If you're developing an IVD device or life science tool, this #Framework is definitely worth referencing. https://lnkd.in/d6GFiYdr Originally written in 2021 & geared to de-risking platforms, we tend to view it now from a more positive, market-launch perspective. How can you step-change your consumable or instrument cost, differentiate from competition, and successfully exit to a strategic? I like thinking about it more positively 😃 Give it a read and see for yourself! #AssayAutomation #LifeScience #IVD #KeyTechInc

Breaking news: Molecular Culture receives FDA Breakthrough Device Designation! We are honored to announce that we have received the FDA's Breakthrough Device Designation for our Molecular Culture ID technology! This designation will greatly help us to bring our diagnostic test to the U.S. market. This exceptional designation is awarded to medical devices that offer significant advantages over existing options, to speed-up clinical implementation of critical innovations in the U.S. It not only accelerates the regulatory review process but also facilitates more efficient reimbursement pathways. Our Molecular Culture ID test can rapidly detect and identify over 200 bacterial species in clinical samples, providing same-day, highly accurate diagnoses. This will lead to quicker, more precise patient treatment, saving lives, and improving patient outcomes. We're grateful for the support from our partners, the European Innovation Council (EIC), and our dedicated team. Together, we're making significant strides in the global fight against antimicrobial resistance. Read more about this exciting milestone and what it means for the future of healthcare in our press release: https://lnkd.in/eRnMSGNW #Inbiome #BreakthroughDevice #MolecularCultureID #Healthcare #InfectiousDiseases #Diagnostics #AMR

#ausbiotech2024 #medicaldevices #CE #ISO13485 #mdsap Come chat with us towards your device journey into global market #commercialisation